Lucas, Brian
Biogen (United States)
3 papers on CoChatORCID 0000-0001-9781-4147
Most cited papers
- Verified
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery
Cell death mechanisms and regulationAcute Myeloid Leukemia Research
Cited by 432
- Verified
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 290
- Verified
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
Amaral, B., Capacci, A., Anderson, T., Tezer, C., Bajrami, B., Lulla, M., Lucas, B., Chodaparambil, J. V., Marcotte, D., Kumar, P. R., et al. (2023) · ACS Chemical Neuroscience
Wnt/β-catenin signaling in development and cancerProtein Kinase Regulation and GTPase Signaling
Cited by 22
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free